Self-assembled nanoparticles based on amphiphilic chitosan derivative and arginine for oral curcumin delivery

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 4397-4412

  Raja, Mazhar Ali ^a   Zeenat, Shah ^a   Arif, Muhammad ^a   Liu, Chenguang ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Cell uptake studies; Curcumin; Cytotoxicity; Nanoparticles; Oral bioavailability; Self assembled

Indexed keywords

ACRYLONITRILE; ARGININE; CHITOSAN DERIVATIVE; CURCUMIN; NANOPARTICLE; SELF ASSEMBLED NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODIFICATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CRITICAL AGGREGATION CONCENTRATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG UPTAKE; EX VIVO STUDY; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MUCOADHESION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRASOUND; ZETA POTENTIAL;

EID: 84988807242     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S106116     Document Type: Article

References (102)

1. World Health Organization [webpage on the Internet]. Cancer. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed February 4, 2016.
2. Akhter S, Ahmad I, Ahmad MZ, et al. Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets. 2013;13(4):362-378.
3. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170-183.
4. Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2008;128(1):23-31.
5. Akhter S, Ahmad Z, Singh A, et al. Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern. Curr Pharm Des. 2011;17(18):1834-1850.
6. International Agency for Research on Cancer [webpage on the Internet]. World Cancer Report 2014. Available from: http://www.iarc.fr/en/ publications/books/wcr/wcr-order.php. Accessed February 4, 2016.
7. Feng SS, Mei L, Anitha P, et al. Poly(lactide)-vitamin E derivative/ montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials. 2009;30:3297-3306.
8. Benival DM, Devarajan PV. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm. 2012;423(2):554-561.
9. Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs III: formulation using drug delivery systems. Drug Discov Today. 2013;18(1-2):99-104.
10. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013; 170(1):15-40.
11. Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs I: general considerations. Drug Discov Today. 2013;18(1-2):25-34.
12. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78(18): 2081-2087.
13. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41(13):1955-1968.
14. Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol. 2012;26(12):1512-1524.
15. Fan X, Zhang C, Liu DB, Yan J, Liang HP. The clinical applications of curcumin: current state and the future. Curr Pharm Des. 2013;19(11): 2011-2031.
16. Lin JK, Lin-Shiau SY. Mechanisms of cancer chemoprevention by curcumin. Proc Natl Sci Counc Repub China B. 2001;25(2):59-66.
17. Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004;90(5):1011-1015.
18. Shelma R, Sharma CP. In vitro and in vivo evaluation of curcumin loaded lauroyl sulphated chitosan for enhancing oral bioavailability. Carbohydr Polym. 2013;95(1):441-448.
19. Dhule SS, Penfornis P, He J, et al. The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma. Mol Pharm. 2014;11(2):417-427.
20. Harada T, Giorgio L, Harris TJ, et al. Diamide linked γ-cyclodextrin dimers as molecular-scale delivery systems for the medicinal pigment curcumin to prostate cancer cells. Mol Pharm. 2013;10(12): 4481-4490.
21. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotech. 2004;113:151-155.
22. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm. 2007;337(1-2):299-306.
23. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotech. 2007;5:3-21.
24. Kumar V, Lewis SA, Mutalik S, et al. Biodegradable microspheres of curcumin for the treatment of inflammation. Indian J Phys Pharmacol. 2002;46:209-217.
25. Sou K, Inenaga S, Takeoka S, Tsuchida E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm. 2008; 352(1-2):287-293.
26. Dhule SS, Penfornis P, Frazier T, et al. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine. 2012;8(4):440-451.
27. Vemula PK, Li J, John G. Enzyme catalysis: tool to make and break amygdalin hydrogelators from renewable resources: a delivery model for hydrophobic drugs. J Am Chem Soc. 2006;128(27):8932-8938.
28. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther. 2007;6(4):1276-1282.
29. Wang D, Veena MS, Stevenson K, et al. Liposome encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT independent pathway. Clin Cancer Res. 2008;14:6228-6236.
30. Zheng H, Zhang XQ, Xiong FL, et al. Preparation, characterization, and tissue distribution in mice of lactosaminated carboxymethyl chitosan nanoparticles. Carbohydr Polym. 2011;83:1139-1145.
31. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1-2):1-20.
32. Ahmad MZ, Alkahtani SA, Akhtar S, et al. Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. J Drug Target. 2016;24(4):273-293.
33. Roldo M, Hornof M, Caliceti P, Bernkop-Schnürch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur J Pharm Biopharm. 2004;57(1):115-121.
34. Malafaya PB, Santos TC, Van Griensven M, Reis RL. Morphology, mechanical characterization and in vivo neo-vascularization of chitosan particle aggregated scaffolds architectures. Biomaterials. 2008; 29(29):3914-3926.
35. Muzzarelli C, Stanic V, Gobbi L, et al. Spray-drying of solutions containing chitosan together with polyuronans and characterisation of the microspheres. Carbohydr Polym. 2004;57:73-82.
36. Jayakumar R, Menon D, Manzoor K, et al. Biomedical applications of chitin and chitosan based nanomaterials-a short review. Carbohydr Polym. 2010;82:227-232.
37. Liu Y, Di Zang H, Kong M, et al. In vitro evaluation of mucoadhesion and permeation enhancement of polymeric amphiphilic nanoparticles. Carbohydr Polym. 2012;89(2):453-460.
38. Jayakumar R, Prabaharan M, Reis RL, Mano JF. Graft copolymerized chitosan - present status and applications. Carbohydr Polym. 2005;62: 142-158.
39. Jayakumar R, Nwe N, Tokura S, Tamura H. Sulfated chitin and chitosan as novel biomaterials. Int J Biol Macromol. 2007;40(3):175-181.
40. Casettari L, Vllasaliu D, Lam JK, Soliman M, Illum L. Biomedical applications of amino acid-modified chitosans: a review. Biomaterials. 2012;33(30):7565-7583.
41. Gao Y, Xu Z, Chen S, Gu W, Chen L, Li Y. Arginine-chitosan/DNA self-assemble nanoparticles for gene delivery: in vitro characteristics and transfection efficiency. Int J Pharm. 2008;359(1-2):241-246.
42. Wernersson E, Heyda J, Kubícková A, Krízek T, Coufal P, Jungwirth P. Effect of association with sulfate on the electrophoretic mobility of polyarginine and polylysine. J Phys Chem B. 2010;114(36): 11934-11941.
43. Park S, Lee SK, Lee KY. Oligoarginine-modified chitosan for siRNA delivery. J Control Release. 2011;152:165-166.
44. Zhu DW, Zhang HL, Bai JG, et al. Enhancement of transfection efficiency for HeLa cells via incorporating arginine moiety into chitosan. Chin Sci Bull. 2007;52:3207-3215.
45. Akagi T, Kaneko T, Kida T, Akashi M. Preparation and characterization of biodegradable nanoparticles based on poly (g-glutamic acid) with l-phenylalanine as a protein carrier. J Control Release. 2005;108: 226-236.
46. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev. 2010;62(1):28-41.
47. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008;60(15): 1650-1662.
48. Behan N, Birkinshaw C, Clarke N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerization and particle formation. Biomaterials. 2001;11:1335-1344.
49. Juan BSD, Briesen HV, Gelperima SE, Kreuter J. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. J Drug Target. 2006;14(9):614-622.
50. Maksimenko O, Pavlov E, Toushov E, et al. Radiation sterilization of doxorubicin bound to poly (butyl cyanoacrylate) nanoparticles. Int J Pharm. 2008;356:325-332.
51. Reddy LH, Sharma RK, Murthy RSR. Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton’s lymphoma tumour. J Drug Target. 2004;12:443-451.
52. Bisht S, Mizuma M, Feldmann G, et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther. 2010;9(8):2255-2264.
53. Huang CY, Chen CM, Lee YD. Synthesis of high loading and encapsulation efficient paclitaxel-loaded poly (n-butyl cyanoacrylate) nanoparticles via miniemulsion. Int J Pharm. 2007;338(1-2):267-275.
54. Miyazaki S, Takahashi A, Kubo W, Bachynsky J, Löebenberg R. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. J Pharm Pharm Sci. 2003; 6(2):240-245.
55. Page-Clisson ME, Pinto-Alphandary H, Ourevitch M, Andremont A, Couvreur P. Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier. J Control Release. 1998;56(1-3): 23-32.
56. Tasset C, Barette N, Thysman S, et al. Polyisobutylcyanoacrylate nanoparticles as sustained release system for calcitonin. J Control Release. 1995;33:23-30.
57. Sun M, Gao Y, Guo CY, et al. Enhancement of transport of curcumin to brain in mice by poly (N-butylcyanoacrylate) nanoparticle. J Nanopart Res. 2010;12:3111-3122.
58. Duan J, Zhang Y, Han S, et al. Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 2010;400(1-2):211-220.
59. Abou-Zeid NY, Waly AI, Kandile NG, et al. Preparation, characterization and antibacterial properties of cyanoethylchitosan/cellulose acetate polymer blended films. Carbohydr Polym. 2011;84:223-230.
60. Yin L, Su T, Chang J, et al. Arginine and acrylonitrile modified chitosan nanoparticles for anticancer drug delivery. Nano. 2014;9: 14500751-14500759.
61. Shigemasa Y, Matsuura H, Sashiwa H, Saimoto H. Evaluation of different absorbance ratios from infrared spectroscopy for analyzing the degree of deacetylation in chitin. Int J Biol Macromol. 1996;18(3):237-242.
62. Sashiwa H, Shigemasa Y. Chemical modification of chitin and chitosan 2: preparation and water soluble property of N-acylated or N-alkylated partially deacetylated chitins. Carbohydr Polym. 1999;39:127-138.
63. Kubota N, Tatsumoto N, Sano T, Toya K. A simple preparation of half N-acetylated chitosan highly soluble in water and aqueous organic solvents. Carbohydr Res. 2000;324(4):268-274.
64. Liu CG, Desai KG, Chen XG, Park HJ. Linolenic acid-modified chitosan for formation of self-assembled nanoparticles. J Agric Food Chem. 2005; 53(2):437-441.
65. Liu Y, Guo R. pH-dependent structures and properties of casein micelles. Biophys Chem. 2008;136(2-3):67-73.
66. Amiji MM. Pyrene florescence study of chitosan self-association in aqueous solution. Carbohydr Polym. 1995;26:211-213.
67. Lee H, Lee K, Park TG. Hyaluronic acid-paclitaxel conjugate micelles synthesis, characterization and antitumor activity. Bioconjug Chem. 2008; 19(6):1319-1325.
68. Jithan AV, Madhavi K, Madhavi M, Prabhakar K. Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. Int J Pharm Investig. 2011; 1(2):119-125.
69. Santos CA, Jacob JS, Hertzog BA, et al. Correlation of two bioadhe-sion assays: the everted sac technique and the CAHN microbalance. J Control Release. 1999;61(1-2):113-122.
70. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 2010;31(25):6597-6611.
71. Anitha A, Maya S, Deepa N, et al. Efficient water-soluble biodegradable polymeric nanocarrier for the delivery of curcumin to cancer cells. Carbohydr Polym. 2011;83:452-461.
72. Liu Y, Kong M, Feng C, et al. Biocompatibility, cellular uptake and biodistribution of the polymeric amphiphilic nanoparticles as oral drug carriers. Colloids Surf B Biointerfaces. 2013;103:345-353.
73. Tao S, Peixin X, Qing L, et al. Graft copolymerization of methacrylic acid onto carboxymethyl chitosan. Eur Polym J. 2003;39:189-192.
74. Arias JL, Gallardo V, Gómez-Lopera SA, Plaza RC, Delgado AV. Synthesis and characterization of poly (ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release. 2001;77(3):309-321.
75. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284.
76. Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvas-cular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999;59(16):4129-4135.
77. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657-3666.
78. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37(3-4):223-230.
79. Li Q, Liu CG, Huang ZH, Xue FF. Preparation and characterization of nanoparticles based on hydrophobic alginate derivative as carriers for sustained release of vitamin D3. J Agric Food Chem. 2011;59(5):1962-1967.
80. Raja MA, Liu C, Huang Z. Nanoparticles based on oleate alginate ester as curcumin delivery system. Curr Drug Deliv. 2015;12(5):613-627.
81. Liu J, Lihua L, Chuantong L, et al. Preparation and characterization of curcumin nanoparticles for improvement of cellular uptake. Carbohydr Polym. 2012;90:16-22.
82. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharmacol. 2007;4(6): 807-818.
83. Yu HL, Huang QR. Enhanced in vitro anti-cancer activity of curcumin encapsulated in hydrophobically modified starch. Food Chem. 2010;119: 669-674.
84. Letchford K, Liggins R, Burt H. Solubilization of hydrophobic drugs by methoxy poly (ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. J Pharm Sci. 2008;97(3):1179-1190.
85. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and phar-macodynamics of curcumin. Adv Exp Med Biol. 2007;595:453-470.
86. Zhang L, Qi Z, Huang Q, et al. Imprinted-like biopolymeric micelles as efficient nanovehicles for curcumin delivery. Colloids Surf B Biointerfaces. 2014;123:15-22.
87. Liu L, Li C, Li X, et al. Biodegradable polylactide/poly(ethylene glycol)/polylactide triblock copolymer micelles as anticancer drug carriers. J Appl Polym Sci. 2001;80:1976-1982.
88. Ruan G, Feng SS. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials. 2003; 24(27):5037-5044.
89. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery- a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
90. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev. 2001; 47(1):83-97.
91. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557-570.
92. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009; 61(2):158-171.
93. Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials. 2007;28(13):2233-2243.
94. Chuah LH, Billa N, Roberts CJ, Burley JC, Manickam S. Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon. Pharm Dev Technol. 2011;18(3):591-599.
95. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 2009;61(11):953-964.
96. Fischer R, Fotin-Mieczek M, Hufnagel H, Brock R. Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides. Chembiochem. 2005;6(12):2126-2142.
97. Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med. 1998;4:1449-1452.
98. Gong CY, Deng SY, Wu QJ, et al. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials. 2013;34(4):1413-1432.
99. Xie X, Tao Q, Zou Y, et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem. 2011;59(17):9280-9289.
100. Gao Y, Wang C, Sun M, et al. In vivo evaluation of curcumin loaded nanosuspensions by oral administration. J Biomed Nanotechnol. 2012; 8(4):659-668.
101. Tsai YM, Jan WC, Chien CF, Lee WC, Lin LC, Tsai TH. Optimised nano-formulation on the bioavailability of hydrophobic polyphenol curcumin in freely-moving rats. Food Chem. 2011;127(3):918-925.
102. Yu H, Huang Q. Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J Agric Food Chem. 2012; 60(21):5373-5379.